Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study.

Daniel PetersonMark Van PoppelWarren BolingPerry SantosJason SchwalbHoward EisenbergAshesh MehtaHeather SpaderJames BotrosFrank D VrionisAndrew KoP David AdelsonBradley LegaPeter KonradGuillermo CalleFernando L ValeRichard BucholzR Mark Richardson

Published in: Bioelectronic medicine (2024)

NCT04539964; August 31, 2020.

Keyphrases

double blind
rheumatoid arthritis
placebo controlled
clinical trial
phase iii
disease activity
phase ii
open label
interstitial lung disease
ankylosing spondylitis
randomized controlled trial
systemic lupus erythematosus
combination therapy
replacement therapy